Trial Of Pembrolizumab And Nintedanib

NCT02856425 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

196

Enrollment

OTHER

Sponsor class

Conditions

Patients With Any Advanced Solid Tumors

Interventions

DRUG: Nintedanib
DRUG: Pembrolizumab

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris